TABLE 1.
Bacterial strains used in this study
| Designation | BFT isoform and activity | Straina | Relevant characteristics | Source or reference |
|---|---|---|---|---|
| WT-ETBF (bft-2) | BFT-2 | B. fragilis 86-5443-2-2 | Piglet isolate | 29 |
| WT-NTBF | None | B. fragilis NCTC 9343 | Transformed with pFD340; human isolate | 9 |
| rETBF (bft-2) | BFT-2 | B. fragilis NCTC 9343 | Transformed with bft2::pFD340 | 9 |
| rNTBF (bft-2 H352Y) | Noneb | B. fragilis NCTC 9343 | Transformed with inactive bft2 H352Y::pFD340 | 8 |
| WT-ETBF (bft-1) | BFT-1 | B. fragilis VPI 13784c | Transformed with pFD340; lamb isolate | This paper |
| WT-ETBF (Δbft1) | Noneb | B. fragilis VPI 13784c | Transformed with pFD340; in-frame chromosomal deletion of bft-1 | This paper |
| WT-ETBF (bft-3) | BFT-3 | B. fragilis Korea 570 | Human blood isolate | 4 |
| BT4001 | None | B. thetaiotaomicron 4001d | Transformed with pFD340 | This paper |
| BT4001 (bft-2) | BFT-2 | B. thetaiotaomicron 4001d | Transformed with bft-2::pFD340 | This paper |
a
All strains used in this study are resistant to clindamycin either naturally or by introduction of pFD340.
b
Biologically inactive BFT or bft deletion mutant.
c
B. fragilis VPI 13784 was originally from Tracy Wilkins (51).